Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a fully integrated biopharmaceutical company focused on developing and commercializing products for unmet medical needs. We currently market a product for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease (to learn more, click here). We also have an investigational drug candidate in development for the prevention of HAE attacks (to learn more, click here).

Both our commercial product and drug candidate in development were identified using Dyax’s proprietary phage display technology. We have broadly licensed this technology and have a portfolio of product candidates being developed by our licensees that we refer to as the Licensing and Funded Research Portfolio (LFRP). This portfolio includes one approved product for which we receive royalties. Additionally, there are multiple product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties (to learn more, click here).

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $28.17
Change (%) 0.20 (0.72)%
Volume 901,300
Data as of Apr 20, 2015 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Apr 16, 2015 Dyax Corp. to Host First Quarter 2015 Earnings Call and Webcast
Apr 13, 2015 Dyax Closes $230 Million Public Offering of Common Stock
Apr 9, 2015 Dyax Corp. to Participate in the 14th Annual Needham Healthcare Conference
Apr 7, 2015 Dyax Announces Pricing of $200 Million Public Offering of Common Stock

More »Calendar of Events

Apr 29, 2015 Dyax Corp. 1Q 2015 Earnings Call

More » Event Archives

Apr 14, 2015 14th Annual Needham Healthcare Conference
Mar 31, 2015 DX-2930 Phase 1b Data Review
Mar 2, 2015 Cowen and Company 35th Annual Health Care Conference
Feb 25, 2015 RBC Healthcare Conference

Featured Financial Reports

Filing Date Title Type Size
Feb 27, 2015 10-K View HTML View PDF 1.2 MB Add to Briefcase
Dec 31, 2014 2014 Annual Report PDF  963.7 KB Add to Briefcase
Add to Briefcase = add file to Briefcase

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?